557-01-7

Basic information

• Product Name: 2-Hydroxypyrimidine
• Synonyms: Pyrimidin-2(5H)-one;2-HYDROXYPYRIMIDINE;2-OXOPYRIMIDINE;PYRIMIDIN-2-OL;TIMTEC-BB SBB004380;2(1h)-pyrimidinone;2-Pyrimidinol;1H-pyrimidin-2-one
• CAS NO: 557-01-7
• Molecular Formula: C₄H₄N₂O
• Molecular Weight: 96.09
• EINECS: 209-149-8
• Product Categories: alcohol;PYRIMIDINE
• Mol File: 557-01-7.mol
• Article Data: 44

Chemical Properties

• Melting Point: 177-178 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 309.2 °C at 760 mmHg
• Flash Point: 140.8 °C
• Appearance: /
• Density: 1.28 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: pK1:2.24(＋1);pK2:9.17(0) (25°C)
• CAS DataBase Reference: 2-Hydroxypyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxypyrimidine(557-01-7)
• EPA Substance Registry System: 2-Hydroxypyrimidine(557-01-7)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-40
• Safety Statements: 22-26-36
• Hazardous Substances Data: 557-01-7(Hazardous Substances Data)

Usage

Purification Methods

It crystallises from EtOH or ethyl acetate. Its solubility in H2O at 20o is 1g/2.2mL. [Albert J Chem Soc 4219 1952, Beilstein 24 III/IV 194.]. 2-Hydroxypyrimidine hydrochloride [38353-09-2] M 132.5, has m 203-205.5o(dec)

InChI:InChI=1/C4H4N2O/c7-4-5-2-1-3-6-4/h1-3H,(H,5,6,7)

Upstream product

• 823-09-6 2-(methylsulfanyl)pyrimidine 
• 71-36-3 butan-1-ol 
• 1722-12-9 2-chloropyrimidine 
• 77287-34-4 formamide 
• 6710-47-0 1-β-D-deoxyribofuranosyl-1,2-dihydropyrimidin-2-one 
• 38353-09-2 2-hydroxypyrimidine hydrochloride 
• 122-31-6 malondialdehyde bis(diethyl acetal) 
• 57-13-6 urea 
• 80927-55-5 4-chloro-1H-pyrimidin-2-one 
• 109-12-6 2-aminopyrimidine 
• 64-19-7 acetic acid 
• 1076-43-3 benzene-d6 
• 513-81-5 2,3-dimethyl-buta-1,3-diene 
• 178620-86-5 1-Phenyl-2-(pyrimidine-2-sulfinyl)-ethanone 

Downstream Products

• 3739-81-9 1-methyl-1H-pyrimidin-2-one 
• 931-63-5 2-methoxypyrimidine 
• 52523-22-5 2-trimethylsilyloxypyrimidine 
• 99272-07-8 [2,2-Dimethyl-5-(pyrimidin-2-yloxymethyl)-[1,3]dioxolan-4-yl]-methanol 
• 99272-05-6 Benzoic acid 2,2-dimethyl-5-(2-oxo-2H-pyrimidin-1-ylmethyl)-[1,3]dioxolan-4-ylmethyl ester 
• 99272-15-8 4-(p-Toluenesulfonyloxymethyl)-5-(2-pyrimidon-1-yl)methyl-2,2-dimethyl-(4S,5S)-1,3-dioxolane 
• 95209-83-9 2-(2-oxopyrimidin-1(2H)-yl)acetic acid 
• 38353-06-9 5-bromo-1H-pyrimidin-2-one 
• 66-22-8 uracil 
• 79387-69-2 5-iodo-2(1H)-pyrimidinone 
• 557-01-7 2-hydroxypyrimidine 
• 5585-14-8 3,4-diphenyl-furazan 2-oxide 
• 178047-66-0 3-Phenyl-5,7a-dihydro-1-oxa-2,3a,5-triaza-inden-4-one 
• 24228-13-5 2-hydroxy-3-phenylpyridine 

Relevant articles and documents

Formation of 3,4-dihydro-2-hydroxy-4-ureidopyrimidine from malonaldehyde and urea

-

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection

The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability, and reduced risk for emergence of drug-resistant virus. We have pursued non-nucleoside NS5B polymerase allosteric inhibitors as combination partners with other direct acting antivirals (DAAs) having a complementary mechanism of action. Herein, we describe the discovery of a potent follow-up compound (BI 207524, 27) to the first thumb pocket 1 NS5B inhibitor to demonstrate antiviral activity in genotype 1 HCV infected patients, BILB 1941 (1). Cell-based replicon potency was significantly improved through electronic modulation of the pKa of the carboxylic acid function of the lead molecule. Subsequent ADME-PK optimization lead to 27, a predicted low clearance compound in man. The preclinical profile of inhibitor 27 is discussed, as well as the identification of a genotoxic metabolite that led to the discontinuation of the development of this compound.

Synthesis, characterization and pharmacological study of 4,5-dihydropyrazolines carrying pyrimidine moiety

A series of 5-bromo-2-(3,5-diaryl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine were prepared under conventional heating as well as microwave reaction condition. The newly synthesized compounds were characterized on the basis of elemental, spectral and single crystal X-ray studies. These new compounds were screened for their antioxidant, anti-inflammatory and analgesic activities. Some of these compounds exhibited potent biological activities compared to the standard drug.